Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2024; 16(4): 550-565
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.550
Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management
Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana
Wattana Leowattana, Pathomthep Leowattana, Department of Clinical Tropical Medicine, Mahidol University, Rachatawee 10400, Bangkok, Thailand
Tawithep Leowattana, Department of Medicine, Srinakharinwirot University, Wattana 10110, Bangkok, Thailand
Author contributions: Leowattana W wrote the paper; Leowattana T and Leowattana P collected the data.
Conflict-of-interest statement: The authors declare no conflicts of interest related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wattana Leowattana, MD, PhD, Full Professor, Department of Clinical Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee 10400, Bangkok, Thailand. wattana.leo@mahidol.ac.th
Received: December 12, 2023
Peer-review started: December 12, 2023
First decision: January 27, 2024
Revised: February 3, 2024
Accepted: March 12, 2024
Article in press: March 12, 2024
Published online: April 27, 2024
Processing time: 134 Days and 2.3 Hours
Core Tip

Core Tip: It is possible to employ a quantitative hepatitis B virus (HBV) core antibody (qAnti-HBc) level as a predictor of therapeutic response, recurrence after hepatitis B surface antigen (HBsAg) loss, and HBsAg seroclearance. Just like other newly identified biomarkers, qAnti-HBc is not a stand-alone diagnostic test that can solve every issue. The information that is now available indicates that it may have a much higher diagnostic and prognostic effectiveness when combined with quantitative HBsAg. Further research involving larger and more variable patients is required to assess the actual usefulness of these biomarkers.